Biogen Names New Spin Off, Bioverativ; Aiming for Early 2017 Launch
The following is an excerpt from FierceBiotech.com To read the article in full, click here.
Biogen previously announced its plan to spin out its blood disorder products and candidates into a separate publicly traded company. The new company will be known as Bioverativ and is slated to launch in early 2017 and trade on the Nasdaq market. It will include commercialized hemophilia drugs Eloctate and Alprolix, which are partnered with Swedish Orphan Biovitrum (Sobi), as well as a pipeline including gene therapy programs for hemophilia A and B, a non-factor bispecific antibody program to treat patients with hemophilia A and those with inhibitors, as well as sickle cell disease research.
Assisting and Advocating for the Bleeding Disorders Community